[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599208":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":38,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"ADARx Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ADX-626","EXPERIMENTAL",null,[13],"Drug: ADX-626",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","siRNA duplex oligonucleotide",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Saline",[15],[28],{"name":29,"affiliation":30,"role":31},"Aditya Patel, MD","ADARx Pharmaceuticals","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Nali Castillo","CONTACT","877-232-7974","info@adarx.com",[39],{"facility":40,"status":41,"city":42,"state":11,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Richmond Pharmacology","RECRUITING","London","SE1 1YR","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-0.12574,51.50853,{"lat":50,"lon":49},[53,57],{"name":54,"role":35,"phone":55,"phoneExt":11,"email":56},"Ulrike Lorch, MD","44 20 7042 5800","volunteer@richmondpharmacology.com",{"name":54,"role":58,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100599208","phase-1-phase-1-study-of-adx-626-in-healthy-participants-100599208",false,"NCT07081503","Phase 1 Study of ADX-626 in Healthy Participants","A Phase 1, Randomized, Blinded, Placebo-Controlled Study to Assess ADX-626 in Healthy Participants","Key Inclusion Criteria:\n\n* Age 18 to 45 years at the time of informed consent\n* Males or women of non-childbearing potential (WONCBP)\n* Willing to comply with all study requirements while participating\n* Suitable venous access for blood sampling.\n* Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg\u002Fm2\n* Normal laboratory results including liver enzymes, hemoglobin, platelet count, and coagulation parameters\n* Willing to use acceptable contraception methods if applicable\n\nKey Exclusion Criteria:\n\n* Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer\n* History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.\n* Current infection\n* Participation in an interventional drug study within the last 90 days",true,"ALL","18 Years","45 Years",{"count":73,"type":74},44,"ESTIMATED","INTERVENTIONAL",[77],"PHASE1","This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).",[80],"Healthy Adult Participants","2026-06-12",{"date":83,"type":84},"2026-06-16","ACTUAL",{"date":86,"type":84},"2025-08-12",{"date":88,"type":74},"2027-01-22",{"name":5,"class":6},1]